**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 79707

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Self-expanding metal stent placement and pathological alterations among obstructive colorectal cancer cases**

Kosumi K *et al*. SEMS and pathological alterations

Keisuke Kosumi, Kosuke Mima, Kosuke Kanemitsu, Takuya Tajiri, Toru Takematsu, Yuki Sakamoto, Mitsuhiro Inoue, Yuji Miyamoto, Takao Mizumoto, Tatsuo Kubota, Nobutomo Miyanari, Hideo Baba

**Keisuke Kosumi,** Department of Gastroenterological Surgery, Kumamoto University, Kumamoto 860-8556, Japan

**Kosuke Mima, Yuki Sakamoto, Mitsuhiro Inoue, Takao Mizumoto, Tatsuo Kubota, Nobutomo Miyanari,** Department of Surgery, National Hospital Organization Kumamoto Medical Center, Kumamoto 860-0008, Japan

**Kosuke Kanemitsu, Takuya Tajiri, Toru Takematsu, Yuji Miyamoto, Hideo Baba,** Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Honjo 860-8556, Kumamoto, Japan

**Author contributions:** Kosumi K, Mima K, Miyanari N and Baba H participated in study conception and design; All authors participated in data acquisition; Kosumi K and Mima K performed the statistical analyses and analyzed the data; Miyanari N and Baba H supervised the work; Kosumi K, Mima K, Miyamoto Y, Miyanari N and Baba H were the major contributors to manuscript preparation; All authors contributed to the manuscript, critically revised it, and approved the final version.

**Corresponding author: Keisuke Kosumi, MD, PhD, Doctor, Surgeon, Surgical Oncologist,** Department of Gastroenterological Surgery, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan. kosumi-kmm@umin.ac.jp

**Received:** September 2, 2022

**Revised:** September 23, 2022

**Accepted:** October 25, 2022

**Published online:**

**Abstract**

BACKGROUND

Experimental studies suggest that self-expanding metal stents (SEMSs) enhance the aggressive behavior of obstructive colorectal cancer. The influence of SEMS placement on pathological alterations remains to be elucidated.

AIM

To determine whether SEMS placement is associated with molecular or pathological features of colorectal carcinoma tissues.

METHODS

Using a nonbiased molecular pathological epidemiology database of patients with obstructive colorectal cancers, we examined the association of SEMS placement with molecular or pathological features, including tumor size, histological type, American Joint Committee on Cancer (AJCC)-pTNM stage, and mutation statuses in colorectal cancer tissues compared with the use of transanal tubes. A multivariable logistic regression model was used to adjust for potential confounders.

RESULTS

SEMS placement was significantly associated with venous invasion (*P* < 0.01), but not with the other features examined, including tumor size, disease stage, mutation status, and lymphatic invasion. In both the univariable and multivariable models with adjustment for potential factors including tumor location, histological type, and AJCC-pT stage, SEMS placement was significantly associated with severe venous invasion (*P* < 0.01). For the outcome category of severe venous invasion, the multivariable odds ratio for SEMS placement relative to transanal tube placement was 19.4 (95% confidence interval: 5.24–96.2). No significant differences of disease-free survival and overall survival were observed between SEMS and transanal tube groups.

CONCLUSION

SEMS placement might be associated with severe venous invasion in colorectal cancer tissue, providing an impetus for further investigations on the pathological alterations by SEMSs in colorectal cancer development.

**Key Words:** Bridge to surgery; Colorectal carcinoma; Obstruction; Stent; Venous invasion

Kosumi K, Mima K, Kanemitsu K, Tajiri T, Takematsu T, Sakamoto Y, Inoue M, Miyamoto Y, Mizumoto T, Kubota T, Miyanari N, Baba H. Self-expanding metal stent placement and pathological alterations among obstructive colorectal cancer cases. *World J Gastrointest Endosc* 2022; In press

**Core Tip:** This study aimed to determine whether self-expanding metal stent (SEMS) placement is associated with molecular or pathological features of colorectal carcinoma tissues. As a result, SEMS placement was significantly associated with venous invasion (*P* < 0.01), but not with the other features examined, including tumor size, disease stage, mutation status, and lymphatic invasion. In both the univariable and multivariable models with adjustment for potential factors including tumor location, histological type, and American Joint Committee on Cancer-pT stage, SEMS placement was significantly associated with severe venous invasion (*P* < 0.01). For the outcome category of severe venous invasion, the multivariable odds ratio for SEMS placement relative to transanal tube placement was 19.4 (95% confidence interval: 5.24–96.2).

**INTRODUCTION**

Colorectal cancer is the third most common cancer in both men and women worldwide[1]. Despite remarkable advances in conventional multidisciplinary therapies for colorectal cancer, including surgery[2], radiotherapy, chemotherapy, and immunotherapy, improvements in clinical outcomes have been limited. Further developments of innovative treatment strategies are aggressively being sought, especially for colorectal cancer with complications, such as obstruction, perforation, and hemorrhage[3]. A considerable number of colorectal cancer patients present with a colonic obstruction, and the incidence is reported as high as 30%[4]. As colonic obstruction might endanger the life of patients, emergent decompression is urgently required. Emergency surgery might be associated with increased morbidity, mortality, stoma rate, and oncological suboptimal resection[4-6]. Therefore, a bridge to surgery approach could be a reasonable treatment strategy to allow for one-stage, or elective resection for obstructive colorectal cancer patients[7].

Self-expanding metal stents (SEMSs) have been used worldwide to rescue intestinal obstruction caused by colorectal cancer as well as benign diseases. Accumulating evidence suggests that SEMS placement results in marked advantages in short-term outcomes including the primary anastomosis rate, postoperative complications, and hospital stay after elective surgery because of patients’ good general condition and adequate bowel preparation before surgery[8-11]. SEMSs might have a critical role of serving as a bridge to surgery for resectable colorectal carcinomas. Despite the efficacy and feasibility of SEMS placement in patients with obstructive colorectal cancer, there are several clinical concerns regarding SEMS placement. One of the major concerns is the risk of worse molecular or pathological malignancy by mechanical damage and pressure to the primary tumor by SEMS placement. In an *in vivo* experiment, peritoneal carcinomatosis and liver metastasis were more frequently observed in the stent group[12]. Additionally, human studies have indicated increased numbers of circulating tumor cells after SEMS placement but not after transanal decompression tube placement[13-15]. Based this evidence, we hypothesized that SEMS placement is associated with molecular or pathological malignancy in colorectal carcinoma tissues.

To test this hypothesis, we used a nonbiased molecular pathological epidemiology database of patients with obstructive colorectal cancer, and examined the molecular and pathological features of tumor tissue according to the decompression methods. Unlike previous studies[16,17], we first diagnosed lymphatic invasion (absent, minimal, moderate, or severe) and venous invasion (absent, minimal, moderate, or severe) in detail based on the Japanese Classification of Colorectal Carcinoma[18], and investigated the association between SEMS placement and molecular or pathological malignancy. We argue that the use of transdisciplinary integrated analyses to obtain a better understanding of the interaction between the decompression technique and tumor tissue characteristics will significantly help in the development of new treatment strategies for obstructive colorectal cancer.

**MATERIALS AND METHODS**

***Study population***

This study included 102 consecutive patients with obstructive colorectal cancer who underwent emergent colonic decompression at the National Hospital Organization Kumamoto Medical Center from July 2012 to December 2020. The main inclusion criteria were an age of > 18 years, histological confirmation of colorectal adenocarcinoma before or after the operation, no other active malignancy, and performance of emergent colonic decompression followed by surgery. The exclusion criteria were neoadjuvant chemotherapy and/or radiotherapy, perforation, peritonitis. The decompression method for each case was determined by tumor board. SEMS or transanal decompression tube placement was performed under both endoscopic and fluoroscopic guidance for obstructive colorectal cancer (CROSS scale 0, 1, or 2)[19]. Patients underwent cleansing enema for bowel preparation and received analgesia and sedation. The stent size and length were chosen according to the measured length of the obstruction. Tumor staging was performed according to the American Joint Committee on Cancer (AJCC) TNM classification (7th edition)[20]. Two institutional pathologists diagnosed histopathological differentiation (well, moderate, or others), lymphatic invasion (absent, minimal, moderate, or severe), and venous invasion (absent, minimal, moderate, or severe) based on the Japanese Classification of Colorectal Carcinoma[18]. Postoperative complications were recorded and graded as defined by the Clavien–Dindo classification system[21]. The term “prognostic marker’’ is used throughout this article according to the REMARK Guidelines[22].

This study was approved by the Human Ethics Review Committee of the National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan (institutional ethics committee number: 1061). The requirement for written informed consent was waived in view of the retrospective nature of the study.

***Statistical analysis***

All statistical analyses were conducted using the JMP program (version 10, SAS Institute, Cary, NC, United States). All *P* values were two-sided, and the two-sided α level of 0.05 was used for all testing.

Our primary analysis (hypothesis testing) involved examination of the associations of the decompression method used (SEMS *vs* transanal tube; as a predictor variable) with lymphatic invasion and venous invasion. All other analyses, including assessments of odds ratios (ORs), represented secondary analyses. We performed multivariable logistic regression analyses to control for potential confounders. The multivariable logistic regression model included variables showing a univariable association (*P* < 0.05) with lymphatic invasion or venous invasion from the decompression method (transanal tube *vs* SEMS), age (continuous), sex (female *vs* male), tumor location (cecum to transverse colon *vs* descending to sigmoid colon *vs* rectum), waiting period (continuous), tumor size (continuous), histological type (well differentiated *vs* moderately differentiated *vs* others), AJCC-pT (T2/T3 *vs* T4), and mutation (absent *vs* present).

To compare characteristics across strata of decompression methods, we used the chi-square test for categorical variables, and an analysis of variance, assuming equal variances for continuous variables. Each of the cross-sectional analyses was secondary.

Overall survival was defined as the time between the operation date and the date of death. Disease-free survival was defined as the time between the operation date and the date of recurrence. The survival time distributions were determined by the Kaplan–Meier method using a log-rank test.

**RESULTS**

***Decompression methods and clinical, pathological, and molecular characteristics***

Among the 102 patients with obstructive colorectal cancer in the nonbiased independent database, 53% were women and the median age was 72.6 years. The most frequent tumor location was descending to sigmoid colon (65 patients, 64%), followed by the rectum (21 patients, 21%) and cecum to transverse colon (16 patients, 16%). Table 1 summarizes the clinical, pathological, and molecular features of the patients stratified according to decompression methods. Seventy-six (75%) patients underwent transanal tube placement, and 26 (25%) patients underwent SEMS placement. SEMS placement was significantly associated with a longer time between decompression and surgery (*P* = 0.035), but not with the other features examined, including tumor size, disease stage, and mutation status (all *P* > 0.08).

Table 2 summarizes the perioperative features of the patients stratified according to decompression methods. SEMS placement was significantly associated with a higher chance of reconstruction (*P* = 0.011), but not with the other features examined, including operation method, procedure, lymph node dissection, and short-term outcomes (all *P* > 0.07).

***Decompression methods and lymphatic or venous invasion***

Table 3 shows the distribution of patients according to the decompression methods and lymphatic invasion or venous invasion. SEMS placement was significantly associated with severe venous invasion (*P* < 0.0001). Table 4 shows the distribution of colorectal cancer cases according to decompression methods (transanal tube *vs* SEMS) and lymphatic or venous invasion in strata of AJCC-pT stage or tumor location. A similar association of SEMS placement with severe venous invasion was observed (*P* < 0.11).

***Logistic regression analyses between decompression methods and venous invasion***

To test our primary hypothesis, we used a logistic regression analysis to assess the association of the decompression method (SEMS *vs* transanal tube) with the degree of venous invasion (Table 5). In both the univariable and multivariable models, SEMS placement was significantly associated with severe venous invasion (*P* < 0.0001). For the outcome category of venous invasion, the univariable OR was 20.9 [95% confidence interval (CI): 5.78–101] for SEMS placement relative to transanal tube placement, and the multivariable OR was 19.4 (95%CI: 5.24–96.2). Similar findings were observed in the sensitivity analyses, in which we performed a multivariable analysis with adjustment for potential factors including tumor location, histological type, and AJCC-pT stage (multivariable OR: 36.7; 95%CI: 7.89–259; *P* < 0.0001). AJCC-pT was significantly associated with severe venous invasion in only the univariable model (*P* = 0.021), and the univariable OR was 3.72 (95%CI: 1.22–12.2) for AJCC-pT4 relative to AJCC-pT2/T3.

Among SEMS group, the waiting period for surgery did not have any association with venous invasion. For the outcome category of venous invasion, the univariable OR was 0.86 (95%CI: 0.46–1.14; *P* = 0.32) for waiting period (for 1-wk increment).

***Exploratory analyses for the influence of stent diameter on lymphatic and venous invasion***

As an exploratory analysis, we determined the influence of stent diameter on lymphatic and venous invasion (Table 6). A larger stent was significantly associated with venous invasion (*P* < 0.0001), and was possibly associated with lymphatic invasion (*P* = 0.055).

***Decompression methods and long-term survival***

As exploratory analyses, a Kaplan-Meier analysis was conducted to assess the influence of SEMS placement on long-term survival. No significant differences of disease-free survival and overall survival were observed (*P* = 0.56 for disease-free survival, *P* = 0.60 for overall survival).

**DISCUSSION**

Evidence indicates marked advantages in short-term outcomes by SEMS placement in patients with obstructive colorectal cancer because of these patients’ good general condition and adequate bowel preparation before surgery[8,9]. Notably, other emerging evidence points to a link between SEMS placement and an increase in the number of circulating tumor cells by mechanical damage and pressure to the primary tumor[12-15]. However, the associations of SEMS placement with the molecular and pathological features of colorectal carcinoma tissues remain to be elucidated. The present study was performed to test the hypothesis that SEMS placement is associated with molecular or pathological malignancy in colorectal carcinoma tissues. We used a nonbiased molecular pathological epidemiology database of patients with obstructive colorectal cancer, and showed for the first time that SEMS placement is independently associated with severe venous invasion in colorectal cancer tissue. Although no significant differences of prognoses were observed, our findings suggest a possible influence of SEMS placement on pathological findings.

A growing body of evidence highlights associations between SEMS placement and short-term clinical outcomes among patients with obstructive colorectal cancer. A systematic review of randomized controlled trials showed that 81% of SEMS placements were technically successful, with 76% of patients achieving restoration of gastrointestinal function[23]. Additionally, a meta-analysis showed that SEMS placement helped to maintain quality of life by allowing food intake and temporal discharge, promoted laparoscopic one-stage surgery without stoma creation, and had morbidity and mortality rates equivalent to those of transanal decompression tube placement[9]. SEMS placement might decrease the rate of permanent stomas, especially in elderly patients[8]. Emerging evidence indicates the safety and feasibility of minimally invasive surgery combined with stent insertion for malignant colonic obstruction[24]. Collectively, colonic stenting followed by laparoscopy is safe and effective with high success rates and low complication rates. However, several points remain to be investigated, such as postoperative chemotherapy[25], the SEMS-related perforation rate (5.0%–8.9%)[8,23,26], perforation-related recurrence[26], the SEMS diameter[27], and the optimal timing from stent placement to surgery[28,29].

Long-term survival of patients with complicated colorectal cancer remains poor despite advances in surgical techniques. Additionally, how SEMS placement impacts long-term survival compared with other procedures, including diverting stomas, transanal tubes, and emergency surgery, remains controversial. A retrospective single- or multicenter observational study and two meta-analyses showed no significant difference in long-term survival between the SEMS group and emergency surgery group among patients with obstructive left-sided colorectal cancer[30-33]. Additionally, one randomized controlled trial showed no prognostic difference between the two groups[34]. One retrospective observational study revealed no significant differences in long-term outcomes between patients with obstructive colorectal cancer who underwent SEMS placement and transanal decompression tube placement as a bridge to surgery[35]. In the current study, no significant differences of disease-free survival and overall survival were observed between SEMS and transanal tube groups. A national, population-based cohort study using propensity score matching suggested that SEMS placement has intermediate-term oncologic outcomes similar to those of a decompressing stoma as a bridge to resection of left-sided obstructive colon cancer[36]. While, a French surgical association multicenter cohort study utilizing a propensity score analysis suggested that SEMS placement might be associated with a worse prognosis than a diverting stoma or immediate surgery for obstructive left-sided colorectal cancer[37,38]. The CODOMO study showed that transanal decompression tube placement might be associated with a worse prognosis than surgery for obstructive left-sided colorectal cancer[30]. For obstructive right-sided colorectal cancer, another population-based observational study demonstrated that the prognosis was significantly better in the decompression tube group than in the SEMS group[39]. SEMS-related perforation or an increased bridging interval to surgery might be a significant risk factor for systemic recurrence[26,29]. With respect to operation methods, laparoscopic surgery after stent placement for obstructive colon cancer might be performed safely with long-term outcomes comparable with those of open surgery[40]. The diameter of the colonic stent might not impact long-term survival[27]. Further research is warranted to investigate the prognostic role of SEMS placement in obstructive colorectal cancer compared with other procedures.

Dissemination of tumor cells has been a major concern in patients who undergo SEMS placement for obstructive colorectal cancer, and several experimental studies have focused on circulating tumor cells in the bloodstream. In 2007, an increase in the level of CK20 mRNA in the peripheral circulation was confirmed after endoscopic colonic stent insertion in patients with colorectal cancer[41]. In an *in vivo* study using a mouse model, peritoneal carcinomatosis and liver metastasis were more frequently observed in the stent group[12]. Moreover, in patients with obstructive colorectal cancer, the plasma levels of cell-free DNA and circulating tumor DNA increased after SEMS placement but not after transanal decompression tube placement; this suggests an oncological risk of SEMS placement in terms of molecular analysis[13-15]. The no-touch isolation technique, which was first proposed in 1952[42], gives first priority to central vascular ligation followed by mobilization of the tumor-bearing segment of the colon. This technique might reduce the spread of circulating tumor cells from the primary tumor site to other organs by ligation of blood vessels first. One retrospective study showed prognostic improvement by the no-touch isolation technique[43], but a large-scale randomized controlled trial failed to confirm the superiority of the no-touch isolation technique in patients with colorectal cancer[44]. In the current study, we found an association of SEMS placement with high severe invasion, but we observed no significant differences of long-term survivals between two groups. Our findings need to be confirmed in future multicenter studies with a larger cohort.

We acknowledge several limitations in our study. First, the sample size was small, and this was a retrospective observational study at a single center. However, our findings are quite significant despite of small sample size. Because the optimal treatment strategy for obstructive colorectal cancer has not been established, our findings should be verified with a larger cohort in a multi-institutional study. Second, the current study was cross-sectional in nature, and the exact mechanisms that underlie the relationship between SEMS placement and severe venous invasion remain uncertain. Our hypothesis was based on several lines of experimental and population-based evidence indicating that mechanical damage and pressure to the primary tumor by SEMS placement increase venous invasion. Comparison of the pathological features between before and after SEMS placement is quite challenging, and the current study which considered the tumor stage and molecular and pathological features must be valuable. Third, we did not investigate the relationship between venous invasion and circulating tumor cells in the bloodstream. Fourth, the pathological findings including the degree of venous invasion were diagnosed based on the Japanese Classification of Colorectal Carcinoma by two pathologists[18], but the diagnosis is assessed by subjective methods. That is another limitation. Future studies are needed to confirm our findings and examine the association of SEMS placement with molecular and pathological features and long-term survival of patients with obstructive colorectal cancer.

A major strength of our study is that it used a molecular pathological epidemiology[45,46] database of patients with colorectal cancer, forming an independent cohort. This database integrates epidemiologic data, clinicopathologic features, and tumor molecular features including the *KRAS*, *BRAF*, or *NRAS* mutation status in colorectal cancer tissue. Our multidisciplinary integrated study based on this human-population colorectal cancer database enabled us to rigorously investigate the association of SEMS placement with the molecular and pathological features of colorectal cancer tissues; we utilized multivariable logistic regression models after controlling for multiple potential confounders such as disease stage, tumor location, and tumor molecular features.

**CONCLUSION**

In conclusion, we have herein shown that SEMS placement might be associated with severe venous invasion in colorectal cancer tissue, providing an impetus for further investigation of the potential interactive roles of SEMS placement and pathological alterations in colorectal cancer tissues. Validation of our findings may provide insights for further investigations on strategies for obstructive colorectal cancer.

**ARTICLE HIGHLIGHTS**

***Research background***

Experimental studies suggest that self-expanding metal stents (SEMSs) enhance the aggressive behavior of obstructive colorectal cancer.

***Research motivation***

The influence of SEMS placement on pathological alterations remains to be elucidated.

***Research objectives***

This study aimed to determine whether SEMS placement is associated with molecular or pathological features of colorectal carcinoma tissues.

***Research methods***

Using a nonbiased molecular pathological epidemiology database of patients with obstructive colorectal cancers, we examined the association of SEMS placement with molecular or pathological feature.

***Research results***

SEMS placement was significantly associated with venous invasion (*P* < 0.01), but not with the other features examined, including tumor size, disease stage, mutation status, and lymphatic invasion. In both the univariable and multivariable models with adjustment for potential factors including tumor location, histological type, and American Joint Committee on Cancer-pT stage, SEMS placement was significantly associated with severe venous invasion (*P* < 0.01).

***Research conclusions***

SEMS placement might be associated with severe venous invasion in colorectal cancer tissue.

***Research perspectives***

Future studies are needed to confirm our findings and examine the association of SEMS placement with pathological features and long-term survival of patients with obstructive colorectal cancer.

**REFERENCES**

1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019; **69**: 7-34 [PMID: 30620402 DOI: 10.3322/caac.21551]

2 **Asari SA**, Cho MS, Kim NK. Safe anastomosis in laparoscopic and robotic low anterior resection for rectal cancer: a narrative review and outcomes study from an expert tertiary center. *Eur J Surg Oncol* 2015; **41**: 175-185 [PMID: 25468455 DOI: 10.1016/j.ejso.2014.10.060]

3 **Kosumi K**, Mima K, Morito A, Yumoto S, Matsumoto T, Inoue M, Mizumoto T, Kubota T, Miyanari N, Baba H. Patient Age and Long-term Survival in Colorectal Cancer Patients Who Undergo Emergency Surgery. *Anticancer Res* 2021; **41**: 1069-1076 [PMID: 33517317 DOI: 10.21873/anticanres.14864]

4 **Gorissen KJ**, Tuynman JB, Fryer E, Wang L, Uberoi R, Jones OM, Cunningham C, Lindsey I. Local recurrence after stenting for obstructing left-sided colonic cancer. *Br J Surg* 2013; **100**: 1805-1809 [PMID: 24227368 DOI: 10.1002/bjs.9297]

5 **Bakker IS**, Snijders HS, Grossmann I, Karsten TM, Havenga K, Wiggers T. High mortality rates after nonelective colon cancer resection: results of a national audit. *Colorectal Dis* 2016; **18**: 612-621 [PMID: 26749028 DOI: 10.1111/codi.13262]

6 **Mege D**, Manceau G, Beyer-Berjot L, Bridoux V, Lakkis Z, Venara A, Voron T, Brunetti F, Sielezneff I, Karoui M; AFC (French Surgical Association) Working Group. Surgical management of obstructive right-sided colon cancer at a national level results of a multicenter study of the French Surgical Association in 776 patients. *Eur J Surg Oncol* 2018; **44**: 1522-1531 [PMID: 30041941 DOI: 10.1016/j.ejso.2018.06.027]

7 **Ahmed O**, Lee JH, Thompson CC, Faulx A. AGA Clinical Practice Update on the Optimal Management of the Malignant Alimentary Tract Obstruction: Expert Review. *Clin Gastroenterol Hepatol* 2021; **19**: 1780-1788 [PMID: 33813072 DOI: 10.1016/j.cgh.2021.03.046]

8 **Amelung FJ**, Borstlap WAA, Consten ECJ, Veld JV, van Halsema EE, Bemelman WA, Siersema PD, Ter Borg F, van Hooft JE, Tanis PJ; Dutch Snapshot Research Group. Propensity score-matched analysis of oncological outcome between stent as bridge to surgery and emergency resection in patients with malignant left-sided colonic obstruction. *Br J Surg* 2019; **106**: 1075-1086 [PMID: 31074507 DOI: 10.1002/bjs.11172]

9 **Matsuda A**, Yamada T, Matsumoto S, Sakurazawa N, Kawano Y, Sekiguchi K, Matsutani T, Miyashita M, Yoshida H. Short-term outcomes of a self-expandable metallic stent as a bridge to surgery vs. a transanal decompression tube for malignant large-bowel obstruction: a meta-analysis. *Surg Today* 2019; **49**: 728-737 [PMID: 30798434 DOI: 10.1007/s00595-019-01784-y]

10 **Spannenburg L**, Sanchez Gonzalez M, Brooks A, Wei S, Li X, Liang X, Gao W, Wang H. Surgical outcomes of colonic stents as a bridge to surgery versus emergency surgery for malignant colorectal obstruction: A systematic review and meta-analysis of high quality prospective and randomised controlled trials. *Eur J Surg Oncol* 2020; **46**: 1404-1414 [PMID: 32418754 DOI: 10.1016/j.ejso.2020.04.052]

11 **Sterpetti AV**, Sapienza P, Fiori E, Marzo LD, Lamazza A. Improved results for left-sided malignant colorectal obstruction with a proper selection for self expandable metal stent placement, surgical resection or diverting stoma. *Eur J Surg Oncol* 2020; **46**: 2064-2067 [PMID: 32739219 DOI: 10.1016/j.ejso.2020.07.020]

12 **Malgras B**, Brullé L, Lo Dico R, El Marjou F, Robine S, Therwath A, Pocard M. Insertion of a Stent in Obstructive Colon Cancer Can Induce a Metastatic Process in an Experimental Murine Model. *Ann Surg Oncol* 2015; **22 Suppl 3**: S1475-S1480 [PMID: 25956578 DOI: 10.1245/s10434-015-4588-y]

13 **Ishibashi R**, Yoshida S, Odawara N, Kishikawa T, Kondo R, Nakada A, Hakuta R, Takahara N, Tanaka E, Sekiba K, Seimiya T, Ohnaga T, Otsuka M, Koike K. Detection of circulating colorectal cancer cells by a custom microfluid system before and after endoscopic metallic stent placement. *Oncol Lett* 2019; **18**: 6397-6404 [PMID: 31807163 DOI: 10.3892/ol.2019.11047]

14 **Takahashi G**, Yamada T, Iwai T, Takeda K, Koizumi M, Shinji S, Uchida E. Oncological Assessment of Stent Placement for Obstructive Colorectal Cancer from Circulating Cell-Free DNA and Circulating Tumor DNA Dynamics. *Ann Surg Oncol* 2018; **25**: 737-744 [PMID: 29235008 DOI: 10.1245/s10434-017-6300-x]

15 **Yamashita S**, Tanemura M, Sawada G, Moon J, Shimizu Y, Yamaguchi T, Kuwai T, Urata Y, Kuraoka K, Hatanaka N, Yamashita Y, Taniyama K. Impact of endoscopic stent insertion on detection of viable circulating tumor cells from obstructive colorectal cancer. *Oncol Lett* 2018; **15**: 400-406 [PMID: 29391884 DOI: 10.3892/ol.2017.7339]

16 **Cao Y**, Yang M, Yan L, Deng S, Gu J, Mao F, Wu K, Liu L, Cai K. Colon metal stents as a bridge to surgery had no significant effects on the perineural invasion: a retrospective study. *World J Surg Oncol* 2020; **18**: 77 [PMID: 32321517 DOI: 10.1186/s12957-020-01845-4]

17 **Hu Y**, Fan J, Xv Y, Hu Y, Ding Y, Jiang Z, Tao Q. Comparison of safety between self-expanding metal stents as a bridge to surgery and emergency surgery based on pathology: a meta-analysis. *BMC Surg* 2020; **20**: 255 [PMID: 33109142 DOI: 10.1186/s12893-020-00908-3]

18 **Japanese Society for Cancer of the Colon and Rectum**. Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3d English Edition [Secondary Publication]. *J Anus Rectum Colon* 2019; **3**: 175-195 [PMID: 31768468 DOI: 10.23922/jarc.2019-018]

19 **Group CSSPR CROSS:ColoRectal Obstruction Scoring System**. Colonic Stent Safe Procedure Research Group. [cited 10 August 2022]. Available from: https://colon-stent.com/001\_mainpage\_en.html

20 **Edge SB**, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC Cancer Staging Handbook. 7th ed. New York: Springer-Verlag, 2010: 143-164

21 **Clavien PA**, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 2009; **250**: 187-196 [PMID: 19638912 DOI: 10.1097/SLA.0b013e3181b13ca2]

22 **McShane LM**, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). *J Natl Cancer Inst* 2005; **97**: 1180-1184 [PMID: 16106022 DOI: 10.1093/jnci/dji237]

23 **Boland PA**, Kelly ME, Donlon NE, Rausa E, Beddy DP, McCormick PH, Mehigan BJ, Larkin JO. Outcomes following colonic stenting for malignant left-sided bowel obstruction: a systematic review of randomised controlled trials. *Int J Colorectal Dis* 2019; **34**: 1625-1632 [PMID: 31475316 DOI: 10.1007/s00384-019-03378-z]

24 **Yang SY**, Park YY, Han YD, Cho MS, Hur H, Min BS, Lee KY, Kim NK. Oncologic Outcomes of Self-Expandable Metallic Stent as a Bridge to Surgery and Safety and Feasibility of Minimally Invasive Surgery for Acute Malignant Colonic Obstruction. *Ann Surg Oncol* 2019; **26**: 2787-2796 [PMID: 30989498 DOI: 10.1245/s10434-019-07346-3]

25 **Kim MH**, Kang SI, Lee J, Oh HK, Ahn S, Kim DW, Kang SB, Shin R, Heo SC, Youk EG, Park SC, Sohn DK, Oh JH, Kim MJ, Park JW, Ryoo SB, Jeong SY, Park KJ; Seoul Colorectal Research Group (SECOG). Oncologic safety of laparoscopic surgery after metallic stent insertion for obstructive left-sided colorectal cancer: a multicenter comparative study. *Surg Endosc* 2022; **36**: 385-395 [PMID: 33492504 DOI: 10.1007/s00464-021-08293-5]

26 **Balciscueta I**, Balciscueta Z, Uribe N, García-Granero E. Long-term outcomes of stent-related perforation in malignant colon obstruction: a systematic review and meta-analysis. *Int J Colorectal Dis* 2020; **35**: 1439-1451 [PMID: 32572603 DOI: 10.1007/s00384-020-03664-1]

27 **Matsuda A**, Yamada T, Takahashi G, Toyoda T, Matsumoto S, Shinji S, Ohta R, Sonoda H, Yokoyama Y, Sekiguchi K, Yoshida H. Does the diameter of colonic stent influence the outcomes in bridge-to-surgery patients with malignant large bowel obstruction? *Surg Today* 2021; **51**: 986-993 [PMID: 33247782 DOI: 10.1007/s00595-020-02185-2]

28 **Neo VSQ**, Jain SR, Yeo JW, Ng CH, Gan TRX, Tan E, Chong CS. Controversies of colonic stenting in obstructive left colorectal cancer: a critical analysis with meta-analysis and meta-regression. *Int J Colorectal Dis* 2021; **36**: 689-700 [PMID: 33495871 DOI: 10.1007/s00384-021-03834-9]

29 **Lim T**, Tham HY, Yaow CYL, Tan IJ, Chan DKH, Farouk R, Lee KC, Lieske B, Tan KK, Chong CS. Early surgery after bridge-to-surgery stenting for malignant bowel obstruction is associated with better oncological outcomes. *Surg Endosc* 2021; **35**: 7120-7130 [PMID: 33433675 DOI: 10.1007/s00464-020-08232-w]

30 **Endo S**, Kumamoto K, Enomoto T, Koizumi K, Kato H, Saida Y. Comparison of survival and perioperative outcome of the colonic stent and the transanal decompression tube placement and emergency surgery for left-sided obstructive colorectal cancer: a retrospective multi-center observational study "The CODOMO study". *Int J Colorectal Dis* 2021; **36**: 987-998 [PMID: 33247313 DOI: 10.1007/s00384-020-03806-5]

31 **Cao Y**, Gu J, Deng S, Li J, Wu K, Cai K. Long-term tumour outcomes of self-expanding metal stents as 'bridge to surgery' for the treatment of colorectal cancer with malignant obstruction: a systematic review and meta-analysis. *Int J Colorectal Dis* 2019; **34**: 1827-1838 [PMID: 31515615 DOI: 10.1007/s00384-019-03372-5]

32 **Jain SR**, Yaow CYL, Ng CH, Neo VSQ, Lim F, Foo FJ, Wong NW, Chong CS. Comparison of colonic stents, stomas and resection for obstructive left colon cancer: a meta-analysis. *Tech Coloproctol* 2020; **24**: 1121-1136 [PMID: 32681344 DOI: 10.1007/s10151-020-02296-5]

33 **Kagami S**, Funahashi K, Ushigome M, Koike J, Kaneko T, Koda T, Kurihara A, Nagashima Y, Yoshino Y, Goto M, Mikami T, Chino K. Comparative study between colonic metallic stent and anal tube decompression for Japanese patients with left-sided malignant large bowel obstruction. *World J Surg Oncol* 2018; **16**: 210 [PMID: 30333034 DOI: 10.1186/s12957-018-1509-0]

34 **Arezzo A**, Forcignanò E, Bonino MA, Balagué C, Targarona E, Borghi F, Giraudo G, Ghezzo L, Passera R, Morino M; collaborative ESCO study group. Long-term Oncologic Results After Stenting as a Bridge to Surgery Versus Emergency Surgery for Malignant Left-sided Colonic Obstruction: A Multicenter Randomized Controlled Trial (ESCO Trial). *Ann Surg* 2020; **272**: 703-708 [PMID: 32833762 DOI: 10.1097/SLA.0000000000004324]

35 **Sato R**, Oikawa M, Kakita T, Okada T, Oyama A, Abe T, Yazawa T, Tsuchiya H, Akazawa N, Ohira T, Harada Y, Tanaka M, Okano H, Ito K, Tsuchiya T. Comparison of the long-term outcomes of the self-expandable metallic stent and transanal decompression tube for obstructive colorectal cancer. *Ann Gastroenterol Surg* 2019; **3**: 209-216 [PMID: 30923791 DOI: 10.1002/ags3.12235]

36 **Veld JV**, Amelung FJ, Borstlap WAA, van Halsema EE, Consten ECJ, Siersema PD, Ter Borg F, van der Zaag ES, de Wilt JHW, Fockens P, Bemelman WA, van Hooft JE, Tanis PJ; Dutch Snapshot Research Group. Comparison of Decompressing Stoma vs Stent as a Bridge to Surgery for Left-Sided Obstructive Colon Cancer. *JAMA Surg* 2020; **155**: 206-215 [PMID: 31913422 DOI: 10.1001/jamasurg.2019.5466]

37 **Mege D**, Sabbagh C, Manceau G, Bridoux V, Lakkis Z, Momar D, Sielezneff I, Karoui M; AFC (French Surgical Association) Working Group. What is the Best Option Between Primary Diverting Stoma or Endoscopic Stent as a Bridge to Surgery with a Curative Intent for Obstructed Left Colon Cancer? Results from a Propensity Score Analysis of the French Surgical Association Multicenter Cohort of 518 Patients. *Ann Surg Oncol* 2019; **26**: 756-764 [PMID: 30623342 DOI: 10.1245/s10434-018-07139-0]

38 **Sabbagh C**, Browet F, Diouf M, Cosse C, Brehant O, Bartoli E, Mauvais F, Chauffert B, Dupas JL, Nguyen-Khac E, Regimbeau JM. Is stenting as "a bridge to surgery" an oncologically safe strategy for the management of acute, left-sided, malignant, colonic obstruction? A comparative study with a propensity score analysis. *Ann Surg* 2013; **258**: 107-115 [PMID: 23324856 DOI: 10.1097/SLA.0b013e31827e30ce]

39 **Suzuki Y**, Moritani K, Seo Y, Takahashi T. Comparison of decompression tubes with metallic stents for the management of right-sided malignant colonic obstruction. *World J Gastroenterol* 2019; **25**: 1975-1985 [PMID: 31086465 DOI: 10.3748/wjg.v25.i16.1975]

40 **Bae SU**, Yang CS, Kim S, Lim DR, Jeong WK, Dong Kim D, Kim JH, Shin EJ, Lee YJ, Lee JY, Kim NK, Baek SK. Long-term oncologic outcomes of laparoscopic versus open resection following stent insertion for obstructing colon cancer: a multi-center retrospective study. *Surg Endosc* 2019; **33**: 3937-3944 [PMID: 30701364 DOI: 10.1007/s00464-019-06680-7]

41 **Maruthachalam K**, Lash GE, Shenton BK, Horgan AF. Tumour cell dissemination following endoscopic stent insertion. *Br J Surg* 2007; **94**: 1151-1154 [PMID: 17541987 DOI: 10.1002/bjs.5790]

42 **Barnes JP**. Physiologic resection of the right colon. *Surg Gynecol Obstet* 1952; **94**: 722-726 [PMID: 14931182]

43 **Turnbull RB Jr**, Kyle K, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technic on survival rates. *Ann Surg* 1967; **166**: 420-427 [PMID: 6039601 DOI: 10.1097/00000658-196709000-00010]

44 **Takii Y**, Mizusawa J, Kanemitsu Y, Komori K, Shiozawa M, Ohue M, Ikeda S, Takiguchi N, Kobatake T, Ike H, Sato T, Tomita N, Ota M, Masaki T, Hamaguchi T, Shida D, Katayama H, Shimada Y, Fukuda H; Colorectal Cancer Study Group of Japan Clinical Oncology Group (JCOG). The Conventional Technique Versus the No-touch Isolation Technique for Primary Tumor Resection in Patients With Colon Cancer (JCOG1006): A Multicenter, Open-label, Randomized, Phase III Trial. *Ann Surg* 2022; **275**: 849-855 [PMID: 35129519 DOI: 10.1097/SLA.0000000000005241]

45 **Ogino S**, Nowak JA, Hamada T, Milner DA Jr, Nishihara R. Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology. *Annu Rev Pathol* 2019; **14**: 83-103 [PMID: 30125150 DOI: 10.1146/annurev-pathmechdis-012418-012818]

46 **Kosumi K**, Baba Y, Okadome K, Yagi T, Kiyozumi Y, Yoshida N, Watanabe M, Baba H. Tumor Long-interspersed Nucleotide Element-1 Methylation Level and Immune Response to Esophageal Cancer. *Ann Surg* 2020; **272**: 1025-1034 [PMID: 30946079 DOI: 10.1097/SLA.0000000000003264]

**Footnotes**

**Institutional review board statement:** This study was approved by the Human Ethics Review Committee of the National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan, No. 1061.

**Informed consent statement:** The requirement for written informed consent was waived in view of the retrospective nature of the study.

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Data sharing statement:** The analysis used anonymous clinical data.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** The Japanese Society of Gastroenterology, No. 51788.

**Peer-review started:** September 2, 2022

**First decision:** September 19, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Fiori E, Italy; He Z, China **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Table 1 Clinical and pathological features of patients with colorectal cancer according to decompression methods**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic**1 | **All cases (*n* = 102)** | **Decompression methods** | ***P* value**2 |
| **Transanal tube (*n* = 76)** | **SEMS (*n* = 26)** |
| **Sex, *n* (%)** |  |  |  | 0.91 |
| Female  | 54 (53) | 40 (53) | 14 (54) |  |
| Male | 48 (47) | 36 (47) | 12 (46) |  |
| **Age, mean ± SD (years)** | 72.6 ± 12.5 | 71.7 ± 12.9 | 75.1 ± 11.1 | 0.24 |
| **Tumor location, *n* (%)** |  |  |  | 0.24 |
| Cecum to transverse colon | 16 (16) | 13 (17) | 3 (12) |  |
| Descending to sigmoid colon | 65 (64) | 45 (59) | 20 (77) |  |
| Rectum | 21 (21) | 18 (24) | 3 (12) |  |
| **Tumor size, mean ± SD (mm)** | 40.7 ± 16.2 | 39.0 ± 14.9 | 45.4 ± 19.3 | 0.086 |
| **Time from decompression to operation,** **mean** **± SD (days)** | 13.6 ± 12.9 | 12.0 ± 7.6 | 18.2 ± 21.7 | 0.035 |
| **Histological type, *n* (%)** |  |  |  | 0.35 |
| Well  | 29 (28) | 19 (25) | 10 (38) |  |
| Moderate  | 67 (66) | 53 (70) | 14 (54) |  |
| Mucinous, poor, or signet-ring cell | 6 (5.9) | 4 (5.3) | 2 (7.7) |  |
| **T stage (depth of tumor invasion), *n* (%)** |  |  |  | 0.57 |
| T1 (submucosa) | - | - | - |  |
| T2 (muscularis propria) | 1 (1.0) | - | 1 (3.9) |  |
| T3 (subserosa) | 67 (66) | 54 (71) | 13 (50) |  |
| T4 (serosa or other organs) | 34 (33) | 22 (29) | 12 (46) |  |
| **N stage (number of positive lymph nodes), *n* (%)** |  |  |  | 0.54 |
| N0 (0) | 49 (48) | 36 (47) | 13 (50) |  |
| N1 (1-3) | 39 (38) | 28 (37) | 11 (42) |  |
| N2 (4-) | 14 (14) | 12 (16) | 2 (7.7) |  |
| **AJCC disease stage, *n* (%)** |  |  |  | 0.40 |
| I | 1 (1.0) | - | 1 (3.9) |  |
| II | 42 (41) | 31 (41) | 11 (42) |  |
| III | 36 (35) | 27 (36) | 9 (35) |  |
| IV | 23 (23) | 18 (24) | 5 (19) |  |
| **Mutation status, *n* (%)** |  |  |  | 0.51 |
| *KRAS* mutated | 34 (43) | 26 (47) | 8 (33) |  |
| *NRAS* mutated | 3 (3.8) | 2 (3.6) | 1 (4.2) |  |
| *BRAF* mutated | 0 (0) | 0 (0) | 0 (0) |  |
| Absent | 42 (53) | 27 (49) | 15 (63) |  |

1Percentage indicates the proportion of patients with a specific clinical characteristic among all patients or in strata of decompression methods.

2We used the chi-square test to compare categorical variables and analysis of variance to compare continuous variables. We adjusted the two-sided α level to 0.05.

AJCC: American Joint Committee on Cancer; SEMS: Self-expanding metal stent.

**Table 2 Perioperative features of patients with colorectal cancer according to decompression methods**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic**1 | **All cases (*n* = 102)** | **Decompression methods** | ***P* value**2 |
| **Transanal tube (*n* = 76)** | **SEMS (*n* = 26)** |
| **Operation method, *n* (%)** |  |  |  | 0.31 |
| Open | 54 (53) | 38 (50) | 16 (62) |  |
| Laparoscopy | 48 (47) | 38 (50) | 10 (38) |  |
| **Conversion to laparotomy, *n* (%)** |  |  |  | 0.072 |
| Absent | 47 (98) | 38 (100) | 9 (90) |  |
| Present | 1 (2.1) | - | 1 (10) |  |
| **Procedure, *n* (%)** |  |  |  | 0.17 |
| Colectomy | 58 (57) | 44 (58) | 14 (54) |  |
| Anterior resection | 37 (36) | 25 (33) | 12 (46) |  |
| Hartmann procedure | 5 (4.9) | 5 (6.6) | - |  |
| Abdominoperineal resection (Miles’ operation) | 2 (2.0) | 2 (2.6) | - |  |
| **Lymph node dissection, *n* (%)** |  |  |  | 0.35 |
| D1 | 3 (2.9) | 3 (4.0) | - |  |
| D2 | 10 (9.8) | 8 (11) | 2 (7.7) |  |
| D3 | 89 (87) | 65 (86) | 24 (92) |  |
| **Reconstruction (except 2 abdominoperineal resection cases), *n* (%)** |  |  |  | 0.011 |
| Absent | 10 (10) | 10 (14) | - |  |
| Present | 90 (90) | 64 (86) | 26 (100) |  |
| **Number of harvested lymph nodes, mean ± SD** | 21.6 ± 12.0 | 21.5 ± 11.8 | 21.7 ± 12.6 | 0.97 |
| **Operation time, mean ± SD (min)** | 241 ± 80 | 234 ± 79 | 263 ± 79 | 0.12 |
| **Blood loss, mean ± SD (g)** | 224 ± 364 | 229 ± 375 | 212 ± 336 | 0.84 |
| **Clavien-Dindo classification, *n* (%)** |  |  |  | 0.22 |
| 0 | 78 (76) | 58 (76) | 20 (77) |  |
| 1 | 5 (4.9) | 5 (6.6) | - |  |
| 2 | 11 (11) | 8 (11) | 3 (12) |  |
| 3 | 7 (7.7) | 5 (6.6) | 2 (7.7) |  |
| 4 | - | - | - |  |
| 5 | 1 (1.0) | - | 1 (3.9) |  |
| **Postoperative hospitalization, mean ± SD (days)** | 18.8 ± 15.1 | 19.3 ± 17.0 | 17.2 ± 6.7 | 0.53 |
| **Postoperative chemotherapy, *n* (%)** |  |  |  | 0.36 |
| Absent | 51 (50) | 36 (47) | 15 (58) |  |
| Present | 51 (50) | 40 (53) | 11 (42) |  |

1Percentage indicates the proportion of patients with a specific clinical characteristic among all patients or in strata of decompression methods.

2We used the chi-square test to compare categorical variables and analysis of variance to compare continuous variables. We adjusted the two-sided α level to 0.05.

SEMS: Self-expanding metal stent.

**Table 3 Pathological features of patients with colorectal cancer according to decompression methods**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic**1 | **All cases (*n* = 102)** | **Decompression methods** | ***P* value**2,3 |
| **Transanal tube (*n* = 76)** | **SEMS (*n* = 26)** |
| **Lymphatic invasion, *n* (%)** |  |  |  | 0.12 (0.020) |
| Absent | 11 (11) | 10 (13) | 1 (3.9) |  |
| Minimal | 41 (40) | 33 (43) | 8 (31) |  |
| Moderate | 32 (31) | 23 (30) | 9 (35) |  |
| Severe | 18 (18) | 10 (13) | 8 (31) |  |
| **Venous invasion, *n* (%)** |  |  |  | < 0.0001 (0.0002) |
| Absent | 19 (19) | 17 (22) | 2 (7.7) |  |
| Minimal | 45 (44) | 37 (49) | 8 (31) |  |
| Moderate | 23 (23) | 19 (25) | 4 (15) |  |
| Severe | 15 (15) | 3 (4.0) | 12 (46) |  |

1Percentage indicates the proportion of patients with a specific clinical characteristic among all patients or in strata of decompression methods.

2We used the chi-square test to compare as categorical variables. We adjusted the two-sided α level to 0.05.

3We used the Mann-Whitney U test to compare as nonparametric continuous variables. We adjusted the two-sided α level to 0.05.

SEMS: Self-expanding metal stent.

**Table 4 Pathological features of patients with colorectal cancer according to decompression methods in strata of American Joint Committee on Cancer-pT stage or tumor location**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic**1 | **All cases (*n* = 102)** | **Decompression methods** | ***P* value**2,3 |
| **Transanal tube (*n* = 76)** | **SEMS (*n* = 26)** |
| ***Lymphatic invasion*** |  |  |  |  |
| **AJCC-pT2/T3 cases, *n* (%)** |  |  |  | 0.024 (0.036) |
| Absent | 8 (12) | 8 (15) | - |  |
| Minimal | 31 (46) | 25 (46) | 6 (43) |  |
| Moderate | 20 (29) | 17 (31) | 3 (21) |  |
| Severe | 9 (13) | 4 (7.4) | 5 (36) |  |
| **AJCC-pT4 cases, *n* (%)** |  |  |  | 0.53 (0.56) |
| Absent | 3 (8.8) | 2 (9.1) | 1 (8.3) |  |
| Minimal | 10 (29) | 8 (36) | 2 (17) |  |
| Moderate | 12 (35) | 6 (27) | 6 (50) |  |
| Severe | 9 (26) | 6 (27) | 3 (25) |  |
| ***Venous invasion*** |  |  |  |  |
| **AJCC-pT2/T3 cases, *n* (%)** |  |  |  | 0.0031 (0.0025) |
| Absent | 13 (19) | 12 (22) | 1 (7.1) |  |
| Minimal | 37 (54) | 32 (59) | 5 (36) |  |
| Moderate | 12 (18) | 9 (17) | 3 (21) |  |
| Severe | 6 (8.8) | 1 (1.9) | 5 (36) |  |
| **AJCC-pT4 cases, *n* (%)** |  |  |  | 0.0077 (0.042) |
| Absent | 6 (18) | 5 (23) | 1 (8.3) |  |
| Minimal | 8 (24) | 5 (23) | 3 (25) |  |
| Moderate | 11 (32) | 10 (45) | 1 (8.3) |  |
| Severe | 9 (26) | 2 (9.1) | 7 (58) |  |
| ***Lymphatic invasion*** |  |  |  |  |
| **Cecum to transverse colon cases, *n* (%)** |  |  | 0.21 (0.088) |
| Absent | 3 (19) | 3 (23) | - |  |
| Minimal | 7 (44) | 6 (46) | 1 (33) |  |
| Moderate | 4 (25) | 4 (31) | - |  |
| Severe | 2 (13) | - | 2 (67) |  |
| **Descending to rectum, *n* (%)** |  |  |  | 0.40 (0.096) |
| Absent | 8 (9.3) | 7 (11) | 1 (4.4) |  |
| Minimal | 34 (40) | 27 (43) | 7 (30) |  |
| Moderate | 28 (33) | 19 (30) | 9 (39) |  |
| Severe | 16 (19) | 10 (16) | 6 (26) |  |
| ***Venous invasion*** |  |  |  |  |
| **Cecum to transverse colon cases, *n* (%)** |  |  | 0.10 (0.078) |
| Absent | 5 (31) | 5 (38) | - |  |
| Minimal | 6 (38) | 5 (38) | 1 (33) |  |
| Moderate | 2 (13) | 2 (15) | - |  |
| Severe | 3 (19) | 1 (7.7) | 2 (67) |  |
| **Descending to rectum, *n* (%)** |  |  |  | 0.0001 (0.0012) |
| Absent | 14 (16) | 12 (19) | 2 (8.7) |  |
| Minimal | 39 (45) | 32 (51) | 7 (30) |  |
| Moderate | 21 (24) | 17 (27) | 4 (17) |  |
| Severe | 12 (14) | 2 (3.2) | 10 (43) |  |

1Percentage indicates the proportion of patients with a specific clinical characteristic among all patients or in strata of decompression methods.

2We used the chi-square test to compare as categorical variables. We adjusted the two-sided α level to 0.05.

3We used the Mann-Whitney U test to compare as nonparametric continuous variables. We adjusted the two-sided α level to 0.05.

AJCC: American Joint Committee on Cancer; SEMS: Self-expanding metal stent.

**Table 5 Logistic regression analyses to assess the association of decompression method (predictor) with severe venous invasion (outcome)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Model for severe venous invasion (*n* = 102, as a binary outcome variable)** | **Univariable** | **Multivariable**1 | **Multivariable**2 |
| **OR (95%CI)** | ***P* value** | **OR (95%CI)** | ***P* value** | **OR (95%CI)** | ***P* value** |
| **Decompression methods** |  |  |  |  |  |  |
| Transanal tube | 1 (reference) | < 0.0001 | 1 (reference) | < 0.0001 | 1 (reference) | < 0.0001 |
| SEMS | 20.9 (5.78-101) |  | 19.4 (5.24-96.2) |  | 36.7 (7.89-259) |  |
| **Age (for 10-yr increment)** | 1.29 (0.82-2.20) | 0.28 |  |  |  |  |
| **Sex** |  |  |  |  |  |  |
| Female | 1 (reference) | 0.60 |  |  |  |  |
| Male | 1.34 (0.44-4.14) |  |  |  |  |  |
| **Tumor location** |  |  |  |  |  |  |
| Cecum to transverse colon | 1 (reference) | 0.27 |  |  | 1 (reference) | 0.27 |
| Descending to sigmoid colon | 0.88 (0.23-4.31) |  |  |  | 0.38 (0.05-2.60) |  |
| Rectum | 0.22 (0.01-1.90) |  |  |  | 0.11 (0.003-1.58) |  |
| **Waiting period (for 1-wk increment)** | 0.91 (0.47-1.22) | 0.64 |  |  |  |  |
| **Tumor size (for 10-mm increment)** | 1.10 (0.78-1.49) | 0.55 |  |  |  |  |
| **Histological type** |  |  |  |  |  |  |
| Well  | 1 (reference) | 0.21 |  |  | 1 (reference) | 0.065 |
| Moderate  | 2.65 (0.65-17.9) |  |  |  | 7.27 (1.27-64.5) |  |
| Mucinous, poor, or signet-ring cell | 6.75 (0.66-72.0) |  |  |  | 10.7 (0.48-342) |  |
| **AJCC-pT** |  |  |  |  |  |  |
| T2/T3 | 1 (reference) | 0.021 | 1 (reference) | 0.084 | 1 (reference) | 0.082 |
| T4 | 3.72 (1.22-12.2) |  | 3.17 (0.86-12.6) |  | 3.76 (0.85-19.4) |  |
| **Mutation** |  |  |  |  |  |  |
| Absent | 1 (reference) | 0.81 |  |  |  |  |
| Present (*KRAS*, *NRAS*) | 1.16 (0.33-4.07) |  |  |  |  |  |

1The multivariable logistic regression model included the decompression method (transanal tube *vs* SEMS), and AJCC-pT (T2/T3 *vs* T4).

2The multivariable logistic regression model included the decompression method (transanal tube *vs* SEMS), tumor location (cecum to transverse colon *vs* descending to sigmoid colon *vs* rectum), histological type (well-differentiated vs. moderately differentiated *vs* others), and AJCC-pT (T2/T3 *vs* T4).

AJCC: American Joint Committee on Cancer; CI: Confidence interval; OR: Odds ratio; SEMS: Self-expanding metal stent.

**Table 6 Pathological features of patients with colorectal cancer according to decompression methods (transanal tube *vs* 18-mm stent *vs* 22-mm stent)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic**1 | **All cases (*n* = 102)** | **Decompression methods** | ***P* value**2,3 |
| **Transanal tube (*n* = 76)** | **18 mm stent (*n* = 11)** | **22 mm stent (*n* = 15)** |
| **Lymphatic invasion, *n* (%)** |  |  |  |  | 0.055 (0.0060) |
| Absent | 11 (11) | 10 (13) | 1 (9.1) | - |  |
| Minimal | 41 (40) | 33 (43) | 5 (45) | 3 (20) |  |
| Moderate | 32 (31) | 23 (30) | 4 (36) | 5 (33) |  |
| Severe | 18 (18) | 10 (13) | 1 (9.1) | 7 (47) |  |
| **Venous invasion, *n* (%)** |  |  |  |  | < 0.0001 (0.0006) |
| Absent | 19 (19) | 17 (22) | 2 (18) | - |  |
| Minimal | 45 (44) | 37 (49) | 3 (27) | 5 (33) |  |
| Moderate | 23 (23) | 19 (25) | 1 (9.1) | 3 (20) |  |
| Severe | 15 (15) | 3(4.0) | 5 (45) | 7 (47) |  |

1Percentage indicates the proportion of patients with a specific clinical characteristic among all patients or in strata of decompression methods.

2We used the chi-square test to compare as categorical variables. We adjusted the two-sided α level to 0.05.

3We used the Mann-Whitney U test to compare as nonparametric continuous variables. We adjusted the two-sided α level to 0.05.